Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Nikole Wollerstein who wrote (111)	10/21/2000 8:12:58 PM
From: Marty	Read Replies (1) of 278

Well, while "buy of a lifetime" was too enthusiastic that early in the game, the story isn't over yet. You could have bought the stock much cheaper since then but that has not been because the drug has disappointed or there is any less promise for it. They are still 3 to 4 years ahead of anyone else in the field. In fact, there was a study just released that indicated that Neotrofin reduced amyloid plaques and they are the only company with a drug with those properties actually in human trials. That wasn't even suspected in Aug 1999. Fortunately, the drug has been proving out and it appears that they are still learning more about it in the trial process. So far, so good. biz.yahoo.com I am not qualified to comment on how simple a compound it is or how specific it is but you may find out more on this on their web site at neotherapeutics.com. I hope you will share your reactions as I am curious as to why, with such potential and this far along in trials, it isn't more generally known. Perhaps there are a lot of other prospects around that are just as promising.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next